Digest Réseau Comment ça marche
Réseau
/
Sociétés
PI
Non vérifié

PIERRE FABRE LABORATORIES

Ce que nous écrivons

Fitness/Bien-êtreIndustrie pharmaceutiqueMédecine - DiversSantéSanté Publique

11 communiqués de presse

Voir tous les communiqués de presse
Press Release cover image
22/06/2026
Santé
Fitness/Bien-être
Médecine - Divers
Laboratoires Pierre Fabre receives European Commission Approval for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
25/05/2026
Santé
Fitness/Bien-être
Médecine - Divers
Pierre Fabre Laboratories receives CHMP positive opinion for BRAFTOVI® (encorafenib) in combination with cetuximab and FOLFOX (fluorouracil, leucovorin, and oxaliplatin) for the first-line treatment of adult patients with BRAFV600E-mutant metastatic colorectal cancer (mCRC)
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
11/03/2026
Santé
Fitness/Bien-être
Médecine - Divers
Science
Matériel informatique
Pierre Fabre Laboratories is exploring the potential of Artificial Intelligence to launch a new generation of clinical studies in dermo-cosmetics
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
12/03/2025
Industrie pharmaceutique
Santé Publique
Économie
Franchises
Entreprises
Biologie
Pierre Fabre Laboratories e RedRidge Bio annunciano la sigla di una partnership per la scoperta e lo sviluppo congiunto di farmaci
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
12/03/2025
Industrie pharmaceutique
Santé Publique
Économie
Franchises
Entreprises
Brevets, marques et droits d'auteur
Biologie
Pierre Fabre Laboratories and RedRidge Bio Announce a Drug Discovery and Co-development Partnership
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
24/10/2024
Industrie pharmaceutique
Santé Publique
Pierre Fabre annuncia il primo paziente trattato nella fase I/II di PFL-002/VERT-002, una terapia mirata per l'NSCLC con alterazioni del gene MET
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
24/10/2024
Industrie pharmaceutique
Santé Publique
Pierre Fabre announce 1st Patient Dosed in Phase I/II of PFL-002/VERT-002, a targeted therapy in NSCLC with MET Alterations
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
08/10/2024
Industrie pharmaceutique
Technologies de l'Information
Télécommunications
Santé Publique
Pierre Fabre Laboratories e Scorpion Therapeutics annunciano il trattamento del primo paziente nella sperimentazione clinica di fase I/II di PFL-241/STX-241, un inibitore selettivo della mutazione mirato al trattamento del carcinoma polmonare non a piccole cellule localmente avanzato o metastatico
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
08/10/2024
Industrie pharmaceutique
Santé Publique
Biologie
Pierre Fabre Laboratories and Scorpion Therapeutics Announce First Patient Dosed in Phase I/II Clinical Trial of PFL-241/STX-241, a Mutant-Selective Inhibitor Intended To Treat Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0
Press Release cover image
30/08/2024
Industrie pharmaceutique
Santé Publique
I laboratori Pierre Fabre ricevono l'approvazione della Commissione europea per BRAFTOVI® (encorafenib) in combinazione con MEKTOVI® (binimetinib) per il trattamento di pazienti adulti con carcinoma polmonare non a piccole cellule (NSCLC) in stadio avanzato con una mutazione BRAFV600E
Source
PIERRE FABRE LABORATORIES
Émetteur
PR News Wire
1.00
0

Détails du contact

Réseaux sociaux

Followers
0
Compatibilité
0